Риназал

Quick links to important sections

Риназал

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Риназал

Quick Facts About Риназал

Property Description
Active ingredient Xylometazoline hydrochloride
Form Nasal spray or nasal drops (aqueous solution)
Pharmacological class Local decongestant, alpha-sympathomimetic agent
Common use Temporary relief of nasal stuffiness
Origin Synthetic compound (imidazoline derivative)

Риназал: Identity, Composition, and Pharmacological Class

Риназал is a pharmaceutical product identified by its single active component, Xylometazoline hydrochloride, and is classified as a local decongestant. This compound is a synthetic imidazoline derivative, recognized clinically for its targeted action as an alpha-sympathomimetic agent, whose function is centered on addressing vascular congestion directly within the nasal mucosa.

The efficacy of Xylometazoline is based on its pharmacological properties, and it has an established role in providing temporary relief from nasal stuffiness associated with conditions like the common cold. Its monotherapy formulation, containing only Xylometazoline, focuses its therapeutic power entirely on its core vasoconstrictive mechanism.

Topical Form and General Therapeutic Purpose

Риназал is formulated for topical administration and is typically supplied as a sterile nasal spray or nasal drops, which are liquid dosage forms prepared in an aqueous solution. This specialized presentation is designed to deliver the medication directly to the surface of the nasal mucous membrane.

This local application is strategic, aiming to maximize the concentration of the decongestant where it is needed most. By initiating rapid and intense localized vasoconstriction, the compound immediately reduces the engorgement and swelling of the nasal tissues. This action serves the primary therapeutic purpose of the medicine: the efficient clearance of nasal passages and the restoration of comfortable breathing. This topical approach provides faster subjective relief than systemic alternatives.

Regulatory References

  1. Xylometazoline in WHO EML

What side effects are possible with Риназал?

Possible Side Effects and Safety Information

The safety profile of Риназал (Xylometazoline hydrochloride) is formally documented in government regulatory sources, detailing adverse reactions by their frequency and the body systems they affect.

Official Adverse Reactions and Frequency

The following side effects are listed in regulatory labeling according to their official frequency classification:

Classification Documented Adverse Reactions System-Organ Class Involved
Common Nasal dryness, discomfort, burning sensation in the nose/throat, headache, nausea. Respiratory, Gastrointestinal, Nervous
Uncommon Epistaxis (nosebleed). Respiratory
Very Rare Hypersensitivity reactions (e.g., angioedema, rash), transient visual impairment, increased or irregular heart rate. Immune System, Eye, Cardiac
Not Known Rebound congestion (rhinitis medicamentosa), hypertension, excitability, restlessness, hallucinations, paranoid delusions. Respiratory, Cardiac, Nervous

Safety Constraints and Exposure Patterns

Specific safety considerations regarding patient conditions and duration of use are documented in official prescribing information:

  • Duration-Related Risk: The development of rebound congestion (worsening nasal swelling) and severe cardiac/CNS effects (e.g., hypertension, anxiety, hallucinations) is explicitly associated with prolonged or excessive use.
  • High-Risk Patient Groups: Use is restricted for individuals with pre-existing conditions such as narrow-angle glaucoma, rhinitis sicca (atrophic rhinitis), severe hypertension, Long QT syndrome, and in patients taking or having recently discontinued MAO inhibitors (within 14 days).
  • Pregnancy and Lactation: Use during pregnancy is generally advised not to occur due to the documented potential for systemic vasoconstrictor effects. Use during lactation should only be on medical advice as excretion into human milk is unknown.

This information establishes the official regulatory boundaries and risk characteristics of the medicine.

Overdose and Emergency Response

Overdose and when to seek help

The information below summarizes the officially documented descriptions of overdose for Xylometazoline hydrochloride (the active ingredient in Риназал) and the regulator-mandated actions required.

Overdose, which can result from excessive use or accidental oral ingestion, may present with a complex, biphasic clinical picture. Symptoms often begin with Central Nervous System (CNS) stimulation, including excitement, agitation, and irritability, potentially followed by severe CNS depression leading to drowsiness, deep sedation, and coma.

System Affected Documented Overdose Signs
Cardiovascular Bradycardia, tachycardia, arrhythmias, hypertension, and hypotension.
CNS Convulsions (seizures), drowsiness, coma, and hypothermia.

Life-Threatening Manifestations and Emergency Actions

Severe overdose can lead to life-threatening outcomes such as respiratory depression, apnea (cessation of breathing), and cardiovascular collapse. Regulatory documents explicitly state that children are more sensitive to systemic absorption, placing them at increased risk for severe CNS depression.

Immediate medical attention is required upon any suspected overdose or accidental ingestion, even if the individual exhibits no immediate signs of discomfort or poisoning. Individuals must contact emergency services or a Poison Information Centre right away.

No specific antidote is known for Xylometazoline overdose. Management is symptomatic and supportive, and hospital monitoring is often required for several hours due to the potential for delayed, severe systemic effects.

Therapeutic Uses of Риназал

Main Uses and Therapeutic Intent

Риназал is a nasal medication primarily used to provide relief from nasal congestion. It belongs to the class of local vasoconstrictors (decongestants) intended to reduce swelling of the mucous membranes in the nasal passages.

Primary Indications

The medication is used to manage respiratory symptoms associated with various conditions, including:

  • Acute Respiratory Diseases: Relief of nasal obstruction caused by inflammatory processes in the upper respiratory tract.
  • Allergic Rhinitis: Management of nasal congestion resulting from seasonal or perennial allergic reactions to pollen, dust, or animal dander.
  • Vasomotor Rhinitis: Treatment of chronic nasal congestion caused by non-allergic triggers that affect the blood vessels in the nasal mucosa.
  • Sinusitis and Eustachitis: Facilitation of mucus drainage by reducing swelling around the openings of the paranasal sinuses and the auditory tube.

Benefits and Mechanism of Action

Риназал acts by stimulating alpha-adrenergic receptors in the smooth muscle of the nasal blood vessels. This stimulation leads to several clinical benefits:

  • Reduction of Edema: By causing the blood vessels to constrict, the medication decreases blood flow to the nasal tissues, which reduces swelling and inflammation.
  • Restoration of Nasal Breathing: As the swelling subsides, the nasal passages widen, allowing for improved airflow and easier breathing through the nose.
  • Facilitation of Drainage: By opening the nasal passages and sinus ostia, the medication helps in the removal of accumulated secretions, which can prevent secondary complications in the sinuses or middle ear.
  • Preparation for Procedures: It may be used to reduce mucosal swelling prior to diagnostic or therapeutic interventions in the nasal cavity.

Regulatory References

  1. DailyMed (NIH) Label Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Риназал?

The population eligibility for Xylometazoline hydrochloride (Риназал) is strictly defined by regulatory authorities and is dependent on age, pre-existing health conditions, and reproductive status.

Contraindications and Restrictions

The medicine is absolutely contraindicated for use in patients with narrow-angle glaucoma, rhinitis sicca (dry rhinitis), a known hypersensitivity to the drug, or a history of surgery exposing the dura mater, such as trans-sphenoidal hypophysectomy. It must not be used by patients receiving Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of cessation.

Age Group Eligibility Rule
Children under 12 Contraindicated for the 0.1% concentration.
Children under 2 Not recommended for the 0.05% concentration.
Adults / Adolescents Permitted (adolescents aged 12+ for 0.1% concentration).

Conditions Requiring Caution

Use requires caution in patients with conditions sensitive to sympathomimetic agents, including hypertension, cardiovascular disease, Long QT syndrome, hyperthyroidism, and diabetes mellitus. The regulatory status during pregnancy is not recommended due to the potential for systemic vasoconstrictor effects, and use while breastfeeding is advised only under medical supervision.

What should I know about interactions with other medicines?

The official interaction profile for Риназал (Xylometazoline hydrochloride) is primarily defined by the potential for pharmacodynamic reinforcement resulting from its classification as an alpha-sympathomimetic agent. This structure outlines specific restrictions for substances that affect the sympathetic nervous system.

Interaction Type Interacting Substance/Class Official Regulatory Statement
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Co-administration is not recommended due to the officially documented risk of inducing a hypertensive crisis.
Timing Restriction MAOIs Use is prohibited in patients who have taken an MAO inhibitor within the 14 days preceding the start of treatment.
Pharmacodynamic Tricyclic or Tetracyclic Antidepressants Concurrent use may lead to an intensification of the sympathomimetic effects, which can potentially result in an increase in blood pressure.
Pharmacodynamic Other Sympathomimetic Agents Co-administration with other sympathomimetics carries an additive risk of hypertension and related cardiovascular effects.

The documented interaction structure strictly focuses on these classes. Regulatory prescribing information does not formally document interactions involving CYP enzymes, drug transporters, food, alcohol, or herbal products. An additional regulatory note is provided for patients with documented long QT syndrome, who may face an increased risk of serious ventricular arrhythmias, which is a population-specific consideration related to the pharmacodynamic risk.

Mechanism of Action

How Риназал Works

The mechanism of action for Риназал (Xylometazoline) is entirely focused on modulating the sympathetic control of blood flow within the nasal passages, defining a mechanistic cascade that progresses from receptor activation to local tissue volume displacement.


Targeted alpha-Adrenergic Receptor Agonism

The drug's primary action is its role as a direct agonist on alpha-adrenergic receptors, predominantly the alpha1 subtype, located on the vascular smooth muscle cells in the nose. By mimicking the body's natural sympathetic signals, this mechanism directly initiates a rapid change in local blood vessel tone towards contraction.


Local Vasoconstriction and Physiological Volume Reduction

Receptor activation triggers a cellular cascade that increases intracellular calcium, forcing the smooth muscles of the nasal blood vessels (arterioles and venous sinuses) to contract intensely. This localized vasoconstriction rapidly reduces the volume of blood pooling in the engorged tissue, resulting in the physical reduction of volume of the nasal mucous membrane.


Limitations Due to Receptor Desensitization

The mechanistic effect is constrained by its own intensity; prolonged or excessive use can lead to receptor desensitization (tachyphylaxis). This condition compromises the ability of the alpha-adrenergic mechanism to function, resulting in rebound vasodilation—a failure of the vasculature to maintain tone even when the drug is present, thereby causing persistent tissue volume expansion.

Dosage and Administration Information

The administration of Риназал (Xylometazoline hydrochloride) is defined by a structured set of guidelines that dictate the route, concentration, frequency, and duration of use.


Administration Principles

The medicine is designed solely for topical nasal administration using a metered nasal spray or nasal drop formulation. This localized approach requires specific pre-application steps, such as gently clearing the nasal passages and priming the pump mechanism before initial use or after a long period of inactivity, to ensure the delivery of a calibrated dose. The guidance mandates that the product is for single-patient use only to prevent the spread of infection.


Dosing and Duration Patterns

The strength and application frequency of the product are based on the user's age. For adults and adolescents (ge 12 years), the 0.1% concentration is specified, with a standard regimen of 1 to 2 sprays or 2 to 3 drops per nostril. Pediatric patients (2 to 12 years) must use the 0.05% concentration, at a dose of 1 to 2 applications per nostril.

The application frequency is set at up to 3 times daily, with a mandatory minimum interval of 8 to 12 hours between doses. Continuous administration is limited to 7 consecutive days. Use beyond this maximum duration, or use for chronic rhinitis, is to be under medical surveillance only. The total daily dose must never be exceeded.

Recent Clinical Evidence

Research Evidence for Common Cold and Acute Rhinitis

Research exploring how symptoms change over time for nasal stuffiness—a core symptom in conditions characterized by fluctuating or episodic manifestations like the common cold—has relied heavily on short-term randomized controlled trials (RCTs). These trials primarily focused on adults presenting with symptoms of acute rhinitis. Studies monitored outcomes related to physical discomfort and daily functioning, such as the perceived blockage of nasal passages, over defined time intervals typically lasting up to 10 days.

Findings describe patterns observed in the studies related to nasal patency (airflow) in the acute phase. The evidence contributes to the broader evidence landscape, including data cited for its long-established use in acute conditions. However, the evidence remains focused on the acute, short-term relief of symptoms.

Types of Outcomes Measured in Trials

Research explores short-term symptom changes using both objective and patient-reported outcomes. Objective measures included specialized instruments to monitor actual nasal airflow (resistance or conductance). Studies also applied instruments examining patient-reported experiences, such as using visual analog scales (VAS) for perceived discomfort to describe how symptom intensity or variability evolved.

Evidence for Supportive Use in Specific Clinical Settings

Research explored the component in contexts such as following certain nasal surgeries and in acute sinusitis. Specific randomized controlled trials examined the component in contexts such as adult patients immediately following nasal surgical procedures, such as septoplasty. The research examined clinical findings, such as the degree of postoperative swelling (edema), and patient-reported symptoms, though the follow-up durations were limited, and the sample sizes were modest.

For acute sinusitis, dedicated primary RCTs focused on long-term sinusitis outcomes are limited. Regulatory bodies rely on evidence related to its vasoconstrictive properties to examine outcomes related to nasal stuffiness. This means certainty remains low for outcomes unique to sinusitis compared to the more extensive evidence base for the common cold.

Duration of Study Follow-up and Long-term Data

Because the body of research primarily focuses on acute or episodic changes, the typical treatment and observation periods in key regulatory-cited studies are short-term, usually lasting no more than 10 days. Long-term effects are not fully established. Studies have not been designed to monitor continuous use or outcomes reflecting the impact of the medicine over months or years.

Research Gaps and Areas of Uncertainty

Data for certain groups remain insufficient. For instance, most robust clinical data is collected from adult populations, and the results apply only to the populations studied. Comparative evidence for its use in special populations, such as older adults or individuals with specific chronic comorbidities, is often lacking in the primary literature. Overall, the research landscape is characterized by data for acute nasal congestion but certainty remains low for effects outside of its short, defined period of use.

Key Studies & References

  1. Xylometazoline Hydrochloride Nasal Solution Label Information (DailyMed)
  2. WHO Model List of Essential Medicines (Relevant Inclusion for Xylometazoline)

Frequently Asked Questions (FAQ)

Common questions about Риназал (FAQ)

Q: How often do people experience side effects with Риназал?

Official regulatory documents classify documented side effects into frequency categories, such as Common, Uncommon, or Very Rare. These classifications indicate how frequently a particular side effect was generally reported during clinical studies or post-marketing surveillance. This approach is used to give a general sense of the expected rate, though specific numerical percentages are typically not provided in the patient information.

Q: How long does it usually take for Риназал to start working?

Studies and official information indicate that the decongestive effect is observed to begin quickly after application. One study examining the response time found that the median time for individuals to report subjective relief from nasal stuffiness was approximately 1.7 minutes. This observed rapid onset is consistent with the medication's intended localized action.

Q: Can Риназал be used for long periods of time?

Official administration guidelines strictly limit the continuous use of this medication to a maximum of seven consecutive days. Prolonged use beyond this limit is associated with specific risks. Excessive use carries the documented risk that the drug’s intended effect duration may become shorter, and it may lead to rebound congestion (a worsening of nasal swelling).

Q: Are there special considerations for pregnant or breastfeeding individuals using Риназал?

Official sources generally advise against the use of the medication during pregnancy due to the potential for systemic effects, which can cause blood vessel constriction throughout the body. For individuals who are breastfeeding, use is advised only under medical supervision because it is not established whether the medication passes into human milk.

Q: Can I stop using Риназал immediately if I feel better?

Regulatory instructions strictly limit use to a maximum of seven days total. If your symptoms improve or fully resolve before reaching this maximum duration, the general principle is to use the medicine only when needed for relief. The total allowed number of doses per day or the total duration limit should not be exceeded.

Q: Can Риназал be used to treat a common cold?

Yes, official regulatory documents indicate that the medication is intended for the temporary relief of nasal stuffiness. This congestion is often associated with conditions such as the common cold.

Q: Does Риназал help with non-allergic nasal issues?

The product is used for the temporary relief of nasal congestion that may be associated with various causes, not only allergies. This includes stuffiness from the common cold and other forms of acute rhinitis (nasal inflammation).

Q: If I miss a dose of Риназал, should I double up the next time?

According to the official product information, if a dose is missed, it should be used as soon as it is remembered. However, official guidelines indicate that the maximum number of doses allowed per day should be strictly adhered to, and one should not double up the next application to compensate for a missed one.

Q: Is Риназал available over the counter or is a prescription required?

Products containing this active ingredient (Xylometazoline hydrochloride) are generally available for purchase without requiring a prescription. They are commonly available from pharmacies and other retail outlets.

Q: Does the medicine contain any ingredients that cause drowsiness?

Official sources note that the active ingredient may cause nervous system effects in some individuals. Reported side effects include trouble in sleeping and nervousness. Adverse effects that include drowsiness have been documented, especially in cases of overdose or when used in infants.

Q: Can I travel with Риназал on an airplane?

For air travel, it is recommended to keep the medication in its original container. General governmental transportation guidance advises that medically necessary liquids, gels, and aerosols are allowed in carry-on bags in reasonable quantities. They must be declared to security officers for inspection.

Q: Is the medication designed for everyday use or only when symptoms are severe?

The medication is intended for short-term, temporary relief of acute nasal stuffiness. Official administration guidelines strictly limit continuous use to a maximum of seven consecutive days to prevent complications from prolonged use.

Q: Is it possible to develop a tolerance to the effects of Риназал over time?

Prolonged or excessive use can lead to a condition known as tachyphylaxis, which is the technical term for developing rapid tolerance. This condition, known as tachyphylaxis, is a documented risk associated with prolonged or excessive use and can result in the decongestive response becoming reduced or shortened.

Q: What does 'systemic absorption' mean in the context of Риназал?

Systemic absorption refers to the process where the medication, after being applied to the nasal membrane, enters the general bloodstream and is distributed throughout the body. Although this is a topical medicine, some absorption can occur, potentially leading to effects on parts of the body outside of the nose.

Q: Is there a link between Риназал and changes in eye pressure?

The presence of narrow-angle glaucoma, a condition of high eye pressure, is listed as an absolute contraindication for use. Official regulatory warnings advise caution for patients with a history of increased pressure within the eye.

Q: What are the official guidelines for driving or operating machinery while using Риназал?

Official documents list potential side effects such as dizziness, blurred vision, or nervousness. Official warnings note that if these symptoms are experienced, the ability to drive or operate machinery may be affected.

Q: Does Риназал contain preservatives that might cause local irritation?

The liquid formulation may contain excipients, such as preservatives, to maintain stability. Official regulatory documents commonly list local side effects like burning, stinging, and dryness in the nose, which may sometimes be related to these components.

Q: What should I do if the spray device stops working or gets clogged?

Official instructions describe that if the spray device is not ejecting the proper dose, the pump mechanism may need to be re-primed. This is usually done by actuating (pumping) it a specific number of times until a fine mist is delivered, restoring the device to its intended function.

Q: Is it normal to feel a temporary sting or burning sensation after application?

Yes, official regulatory documents list a burning sensation in the nose and throat as a Common adverse reaction. This indicates that it is a frequently observed and generally expected effect following application.

Q: Can I use Риназал if I recently had nasal surgery?

Use is absolutely contraindicated if a patient has had surgery that exposes the dura mater (part of the lining of the brain). For patients with any other recent nasal surgery, official warnings state that a healthcare professional should be consulted before using this medication.

Q: Are there specific warnings for people with liver or kidney conditions?

Official warnings indicate that a healthcare professional should be consulted before using the medication if a patient has underlying medical conditions, including liver or kidney disease.

Q: Why do some patient information leaflets advise against using Риназал after a certain number of days?

The strict time limit, typically seven consecutive days, is advised to prevent the potential development of rebound congestion (rhinitis medicamentosa). This rebound swelling is a documented risk of prolonged or excessive use and can lead to a dependence on the spray.

Q: Are there specific patient groups where the use of Риназал requires closer monitoring?

Official warnings advise that use requires caution and closer monitoring in specific patient populations. These include individuals with conditions sensitive to sympathomimetic agents, such as cardiovascular disease, hypertension, or diabetes mellitus.

How should Риназал be stored and disposed of?

How to Store and Dispose of Риназал?

Storage and disposal instructions for Риназал (Xylometazoline hydrochloride) are based strictly on official regulatory labeling, ensuring product stability and safety.

Official Storage Requirements

Storage Condition Requirement
Temperature Store at Controlled Room Temperature, between 20 C and 25 C.
Protection Do not freeze the product.
Packaging Keep in the original container and keep the container tightly closed.
Child Safety Must be kept out of the reach and sight of children.

Disposal Instructions

Unused or expired nasal spray must be disposed of according to local regulatory guidelines. The preferred method is using an authorized drug take-back program. If take-back options are unavailable, the medicine must be prepared for household trash by mixing it with an undesirable substance (e.g., used coffee grounds) and sealing it in a container. The product must not be flushed down a toilet or poured down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Риназал found in:

A-Z Index: